Kali-Sterop

Potassium Chloride, the active ingredient in Kali‑Sterop, is an electrolyte supplement presented as an intravenous solution for intravenous use. It is employed to correct low blood potassium levels and to provide potassium replacement in patients at risk of hypokalemia. It is indicated for patients with documented potassium deficiency, including those receiving diuretics, undergoing surgery, or experiencing gastrointestinal losses.

GNH USA supplies Kali‑Sterop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Kali‑Sterop is used to restore potassium balance in conditions where electrolyte depletion occurs. - Hypokalemia: restores normal serum potassium levels and reduces symptoms such as muscle weakness and cardiac arrhythmias. - Potassium replacement therapy during diuretic treatment: replenishes potassium lost due to increased urinary excretion. - Pre‑operative preparation: corrects potassium deficits before surgery to minimize peri‑operative cardiac risk.

Intravenous potassium chloride may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Infusion site pain or irritation: mild discomfort at the injection site. - Nausea or vomiting: transient gastrointestinal upset. - Transient hypotension: brief drop in blood pressure during rapid infusion. - Headache: mild cephalic discomfort. - Dizziness or light‑headedness: sensation of unsteadiness.

Serious or Rare Side Effects: - Severe hyperkalemia: life‑threatening elevation of serum potassium causing cardiac arrhythmias. - Cardiac arrest: sudden loss of heart function due to electrolyte imbalance. - Anaphylactic reaction: rare severe allergic response with bronchospasm and hypotension. - Pulmonary edema: fluid accumulation in lungs from rapid infusion. - Metabolic acidosis: rare disturbance of acid‑base balance.

Before administering Kali‑Sterop, clinicians should evaluate patient factors and monitor laboratory values to minimize risks. - Renal impairment: assess kidney function and adjust dose to avoid potassium accumulation. - Cardiac disease: monitor ECG for arrhythmias in patients with existing heart conditions. - Existing hyperkalemia: avoid use if serum potassium is already elevated. - Concurrent potassium‑sparing agents: discontinue or adjust dosage of diuretics, ACE inhibitors, or NSAIDs. - Serum potassium monitoring: check levels before, during, and after infusion. - Store below 25°C: keep in original container, protect from light and moisture.

Potassium chloride can interact with several medications that affect potassium balance or cardiac conduction.

Major Interactions (Avoid): - ACE inhibitors or ARBs: may cause additive hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of dangerous potassium excess. - Trimethoprim‑sulfamethoxazole: reduces renal potassium excretion, heightening hyperkalemia risk. - NSAIDs: impair renal potassium elimination, potentially leading to accumulation. - Heparin therapy: can induce hypo‑ or hyperkalemia through aldosterone suppression.

Moderate Interactions (Monitor Closely): - Digoxin: elevated potassium can potentiate digoxin toxicity. - Beta‑blockers: may mask symptoms of hyperkalemia. - Insulin or glucose therapy: shifts potassium intracellularly, affecting serum levels. - Aminoglycoside antibiotics: may cause renal dysfunction influencing potassium handling. - Corticosteroids: can alter potassium distribution.